|
Kidney Failure, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HBP levels were significantly higher in patients developing AKI stage 3 (P < 0.01) compared to AKI stage 0 and 1.
|
28585315 |
2017 |
|
Left Bundle-Branch Block
|
0.020 |
Biomarker
|
disease |
BEFREE |
With HBP, we corrected the LBBB in 81% of patients (n = 39), and we achieved cardiac resynchronization through permanent HBP in 92% of these patients (n = 36).
|
31746996 |
2020 |
|
Left Bundle-Branch Block
|
0.020 |
Biomarker
|
disease |
BEFREE |
HBP provides a promising alternative pacing option that might provide symptom resolution to patients with a painful LBBB syndrome.
|
30497723 |
2019 |
|
Septicemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HBP levels were significantly higher in patients with sepsis non-shock than in those with local infections (median 49.7ng/mL vs 11.8 ng/mL, p<0.01) at enrolment.
|
31015272 |
2019 |
|
Septicemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
HBP has a major role in the pathophysiology of severe bacterial infections and thus represents a potential diagnostic marker and a target for the treatment of sepsis.
|
28370601 |
2017 |
|
Sepsis
|
0.020 |
Biomarker
|
disease |
BEFREE |
HBP has a major role in the pathophysiology of severe bacterial infections and thus represents a potential diagnostic marker and a target for the treatment of sepsis.
|
28370601 |
2017 |
|
Sepsis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HBP levels were significantly higher in patients with sepsis non-shock than in those with local infections (median 49.7ng/mL vs 11.8 ng/mL, p<0.01) at enrolment.
|
31015272 |
2019 |
|
Chronic small plaque psoriasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The results demonstrate the safety and effectiveness of HBP Lotion in the treatment of plaque psoriasis.
|
28301619 |
2017 |
|
Chronic small plaque psoriasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
OBJECTIVE: To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis.
|
31424709 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Vigilin, a nucleocytoplasmic shuttling protein, post-transcriptionally suppresses proto-oncogene c-fms expression (encoding CSF-1R) in breast cancer by binding to a 69 nt cis-acting 3-UTR element in CSF-1R mRNA.
|
30292064 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.
|
20974809 |
2011 |
|
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The HBP joins a handful of online registries worldwide that assess and monitor a large cohort of individuals at risk of AD.
|
30909237 |
2019 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To determine whether HBP (also called vigilin) might be expressed in human atherosclerosis, immunohistochemistry and in situ hybridization were performed on coronary arteries of 18 patients.
|
9409201 |
1997 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To determine whether HBP (also called vigilin) might be expressed in human atherosclerosis, immunohistochemistry and in situ hybridization were performed on coronary arteries of 18 patients.
|
9409201 |
1997 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our pilot data suggest decreased vigilin protein expression, along with shift from the nucleus to the cytoplasmic location, in the transition to ductal carcinoma in situ.
|
30292064 |
2019 |
|
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vigilin is increased in ischemia brain slices and exhibits enhanced release from cultured hippocampal neurons after oxygen glucose deprivation in vitro.
|
30993971 |
2019 |
|
Toxic Epidermal Necrolysis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified HDLBP, which encodes the RNA-binding protein vigilin, as a candidate tumor suppressor deleted at 2q37.3 in greater than one out of ten tumors across multiple tissues of origin.
|
25129143 |
2014 |
|
Graves Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Similarly, minor differences only (P=0.042-0.002) were detected in two HDLBP and two TEKT1 Tag SNPs in the combined UK GD collection.
|
20442750 |
2010 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF.
|
28985325 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified a set of genes including CTBP2, NADK, AZU1, CTSH, FSTL1, and HDLBP showing the highest accuracy more than 69.44 % to classify TKI response in CML patients.
|
27534394 |
2016 |
|
Hyperlipoproteinemia Type I
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We herein present a case of LPL deficiency due to novel combined mutations of glycosylphosphatidylinositol (GPI)-anchored high-density lipoprotein (HDL)-binding protein 1 (GPIHBP1) in a patient with coronary artery disease (CAD).
|
23831619 |
2013 |
|
Liver Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We discovered that vigilin expression increased progressively from the liver cirrhosis tissue to adjacent non-tumor liver tissue and then to HCC tumor cells.
|
24676454 |
2014 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF.
|
28985325 |
2018 |
|
Small cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
While the inhibitor of HDLBP has been reported, our work suggested a promising potential of targeting HDLBP to improve the treatment of fatal SCLC and a powerful tool of using cell-SELEX in cancer medicine.
|
31233742 |
2019 |
|
Hepatocellular Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, iso- or hyperintensity of hepatocellular adenomas on HBP does not necessarily correspond to an increased hepatospecific contrast-agent uptake.
|
30937584 |
2019 |